10-23-03 1644

Attorney Docket No. 037003-0280647
Client Ref. No. 1992-30-0029CP1C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Anderson, et al.	)	Examiner: Schwadron, R.
Serial No:	09/911,703	)	Art Unit: 1644
Filed:	July 25, 2001	)	
Title:	THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA	)	

Certificate of Mailing Under §1.10

I, Patricia Munoz, hereby certify that this paper or fee is being deposited with the United States Postal Service as Express Mail Post Office to Addressee service, Express Mailing Label No. EL 989 437 559 US, under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date.

Date: Oct 21, 2003

By: Patricia Munoz
Patricia Munoz

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the information on the attached Form PTO-1449 be considered by the Office during the pendency of the above-entitled application, pursuant to 37 C.F.R. 1.97. In accordance with 37 C.F.R. 1.97(h), the filing of the Information Disclosure Statement shall not constitute an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b). In the interest of full and complete disclosure to the Office, some or all of the art cited herein may not be considered by Applicant(s) or the Undersigned to be material under the standards of materiality defined in C.F.R. 1.56(b), enacted March 16, 1992, as amended September 8, 2000, and may merely be technical background which may be of interest to the Examiner.

Attorney Docket No. 037003-0280647
Client Ref. No. 1992-30-0029CP1C2

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Since no Office Action on the merits has issued, Applicant believes that no fee is due in connection with the filing of this Information Disclosure Statement. However, please charge any fees that may be necessary to Deposit Account No. 03-3975, Order No. 037003-0280647. A duplicate copy of this transmittal is enclosed for accounting purposes.

Respectfully submitted,

Date: October 21, 2003

Suzanne L. Biggs
Registration No. 30,158 **for**

Thomas A. Cawley, Jr.
Registration No. 40,944
PILLSBURY WINTHROP LLP
1600 Tysons Boulevard
McLean, VA 22102
Telephone: (703) 905-2000
Fax Line: (703) 905-2500
Direct Line: (858) 509-4095

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003-0280647	1992-30-0029CP1C2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Anderson, et al.

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Date: October 21, 2003 Page 1 of 3

Examiner: Scwadron, R. Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Dat (if appropriate)
	AR	5,500,362	03/1996	Robinson, et al.	435	7.23	
	BR	5,648,267	07/1997	Reff	435	320.1	
	CR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation R adily Availabl	
							Enclosed	No	Enclos	No
	DR	0 125 023 A1	11/1984	EP	Cabilly, et al.					
	ER	0 125 023 B1	11/1984	EP	Cabilly, et al.					
	FR	0 125 023 B2	03/2002	EP	Cabilly, et al.					
	GR	0 173 494 A2	03/1986	EP	Morrison, et al.					
	HR	0 274 394 A2	07/1988	EP	Robinson, et al.					
	IR	0 274 394 A3	07/1988	EP	Robinson, et al.					
	JR	0 451 216 B1	01/1996	EP	Queen, et al.					
	KR	0 682 040 A1	11/1995	EP	Queen, et al.					
	LR	0 682 040 B1	11/1995	EP	Queen, et al.					
	MR	WO 88/04936	07/1988	WO	Robinson, et al.					
	NR	WO 92/07466	05/1992	WO	Hellström, et al.					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

		Adams, R.A. *et al.*, Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2, *Can Res 28*:1121-1125 (1968).
		Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, *Can. Res. 27*:2479-2482 (1967).
		Anderson, K.C., et al., Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow, Blood 69(2):597-604 (1987)
		Anderson, D.R., et al., Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody, The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.
		Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation, Blood 63(6):1424-1433 (1984)
		Appelbaum, F.R., Radiolabel d Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. *Hem. Onc. Clinics of N.A. 5(5)*:1013-1025 (1991).
		Armitage, J.O. *et al.*, Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), *Cancer 50*:1695 (1982).
		Bhan, A.K., et al., Stages of B cell differentiation in human lymphoid tissue, J. Exp. Med., 154:737-749 (1981)

		Boulianne, G.L. *et al.*, Production of functional chimaeric mouse/human antibody, *Nature 312*:643 (December 1984).				
		Brunner, K.T. *et al.*, Quantitative assay of the lytic action of immune lymphoid cells on ^{51}Cr-labeled allogeneic target cells *in vitro*; inhibition by isoantibody and drugs, *Immunology 14*:181-189 (1968).				
		Buchsbaum, D.J., et al., A comparison of ^{131}I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts, Int. J. Radiation Oncology Biol. Phys., 18:1033-1041 (1990)				
		Buchsbaum, D.J., et al., Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies, Cancer Research (Suppl.) 50:993s-999s (1990)				
		Buchsbaum, D.J., et al., Comparison of ^{131}I- and ^{90}Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts, Int. J. Radiation Oncology Biol. Phys. 25:629-638 (1993)				
		Calvert, J.E., et al., Cellular events in the differentiation of antibody-secreting cells, Seminars in Hematology, 21(4):226-243 (1984)				
		Chomczynski, P. *et al.*, Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, *Anal. Biochem. 162*:156-159 (1987).				
		Clark, E.A., et al., Role of the Bp35 cell surface polypeptide in human B-cell activation, Proc. Natl. Acad. Sci. USA, 82:1766-1770 (1985)				
		Cope, Antibody shows promise in treating B-cell lymphoma, Oncology, 8(4):100 (1994)				
		DeNardo, S.J., et al., Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, Antibody, Immunoconjugates, and Radiopharmaceuticals, 1(1):17-33 (1988)				
		DeNardo, S.J., et al., The biologic window for chimeric L6 radioimmunotherapy, Cancer 73(3):1023-32 (1994)				
		Dickson, Scientists produce chimeric monoclonal abs, *Genetic Engineering News 5/3* (March 1985).				
		Eary, J.F. *et al*, Imaging and Treatment of B-Cell Lymphoma, *J. Nuc. Med. 31/8*:1257-1268 (1990).				
		Einfeld, D.A. *et al.*, Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, *EMBO 7*:711 (1988)				
		Golay, J.T., et al., The CD20 (Bp35) antigen is involved in activation of B cells from the G_0 to the G_1 phase of the cell cycle, J. Immunology 135(6):3795-3801 (1985)				
		Goldenberg, D.M. *et al.*, Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, *J. Clin. Onc. 9/4*:548-564 (1991).				
		Greenberger, J.S., et al., Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture, Cancer Research 45:758-767 (1985)				
		Hekman, A., et al., Immunotherapy, The Netherlands Cancer Institute Amsterdam Annual Report, pp. 47-48 (1993)				
		Lipton, J.M., et al., Distribution of B1, calla, β2 microglobulin and Ia on hematopoietic progenitors and hematopoiesis supporting cells (HSC) in short and long-term cultures, Blood, 60(5) (Suppl. 1):170a (Abstract 609) (1982)				
		Kaminski, M.G. *et al.*, "Radioimmunotherapy of B-cell lymphoma with [^{131}I] anti-B1 (anti-CD20) antibody, *NEJM 329/7* (1993).				
		Liu, A.Y. *et al.*, Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity. *J. Immun. 139/10*:3521-3526 (1987).				
		Marx, Antibodies made to order, *Science 229* 455 (August 1985).				
		Morrison, S.L, *et al.*, Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, *PNAS 81*:6851-6854 (November 1984).				
		Morrison, Transfectomas provide novel chimeric antibodies, *Science 229*:1202-1207 (September 1985).				
		Munro, Uses of chimaeric antibodies, *Nature 312*:597 (December 1984).				
		Nadler, L.M., et al., B cell origin of non-T cell acute lymphoblastic leukemia a model for discrete stages of neoplastic and normal pre-B cel differentiation, J. Clin. Invest. 74:332-340 (1984)				

		Nadler, L.M., et al., Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma, The Lancet, Vol. II, pp. 427-431 (1984)				
		Nadler, L.M., et al., Seroth rapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, Cancer Research, 40:3147-3154 (1980)				
		Neuberger, M.S. *et al.*, A hapten-specific chimaeric IgE antibody with human physiological effector function, *Nature 314*:268 (March 1985).				
		Oettgen, H.C., et al., Further biochemical studies of the human B-cell diff rentiation antigens B1 and B2, Hybridoma, 2(1):17-28 (1983)				
		Ozato, K., et al., Monoclonal antibodies to mouse MHC antigens III. Hybridoma antibodies reacting to antigens to the H-2^b haplotype reveal genetic control of isotype expression, J. Immunology, 126(1):317-321 (1981)				
		Press *et al.*, Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, *Blood* 69(2):584-591 (1987)				
		Press, O.W. *et al.*, "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." *New England Journal of Medicine 329/17*: 1219-12223 (1993).				
		Press, O.W. *et al.*, "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, *J. Clin. Onc. 7/8*:1027-1038 (1989)				
		Reff, M., et al., Depletion of a B cells *in vivo* by a chimeric mouse human comoclonal antibody to CD20, J. Cellular Biochem., Suppl. 17E:260 (Abstract T103) (1993)				
		Reff, M., et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83(2):435-445 (1994)				
		Robertson, M.J., et al., Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia, Blood, 79(9):2229-2236 (1992)				
		Robinson, R.D. *et al.*, "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," *Hum. Antibod. Hybridomas 2*:84-93 (1991).				
		Sahagan *et al.*, A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, *J. Immunol. 137*:1066-1074 (1986).				
		Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, *Harvey Lectures 69*:125-143 (1974).				
		Schlom J., et al., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, J. Natl. Cancer Inst., 82(9):763-771 (1990)				
		Shulman, M. *et al.*, A better cell line for making hybridomas secreting specific antibodies, *Nature 276*:269 (1978).				
		Smeland, E.B., et al., Activation of human B cells: Alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells, J. Immunology, 138(10):3179-3184 (1987)				
		Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, *Nucl. Med. Bio. 18(6)*: 589-603 (1991).				
		Sun, L.K. *et al.*, Chimeric antibodies with 17-1A-derived variable and human constant regions, *Hybridoma 5/1*:517 (1986).				
		Tan *et al.*, A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, *J. Immunol. 135*:8564 (November 1985).				
		Tedder, T.F., et al., The B cell surface molecule B1 is functionally linked with B cell activation and differentiation, J. Immunology, 135(2):973-979 (1985)				
		Urlaub, G. *et al.*, Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." *Som. Cell & Mol. Gen. 12/6*:555-566 (1986).				
		Valentine, M.A. *et al.*, Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, *J. Biol. Chem. 264(19)*:11282-11287 (1989).				
		Wessels, B.W., et al., Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies, Med. Phys., 11(5):638-645 (1984)				

Examiner	Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Includ copy of this form with next communication to Applicant.